Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects

World Journal of Gastroenterology

Volumn 20, Issue 42, 2014, Pages 15499-15517

  Møller, Søren ^a   Henriksen, Jens H ^a   Bendtsen, Flemming ^b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ascites; Bacterial translocation; Cirrhotic cardiomyopathy; Fibrogenesis; Hepatopulmonary syndrome; Hepatorenal syndrome; Infections; Inflammation; Portopulmonary hypertension; Splanchnic haemodynamics; Systemic circulation

Indexed keywords

ANTIBIOTIC AGENT; VASOACTIVE AGENT;

ACUTE KIDNEY FAILURE; ADRENAL FUNCTION; ARTICLE; BACTERIAL TRANSLOCATION; CARDIOMYOPATHY; CHRONIC LIVER FAILURE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; END STAGE LIVER DISEASE; FIBROGENESIS; HEART FUNCTION; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; KIDNEY FUNCTION; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG QT SYNDROME; LUNG FUNCTION; METABOLIC DISORDER; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; REGULATORY MECHANISM; SPLANCHNIC BLOOD FLOW; SURVIVAL; SYSTEMIC CIRCULATION; SYSTOLIC DYSFUNCTION; VASODILATATION; ANIMAL; COMPLICATION; HEMODYNAMICS; HYPERTENSION, PORTAL; LIVER; LIVER CIRCULATION; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; HEMODYNAMICS; HOMEOSTASIS; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRCULATION; LIVER CIRRHOSIS; MULTIPLE ORGAN FAILURE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84912078809     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i42.15499     Document Type: Article

References (204)

1. Sherlock's Diseases of the Liver and Biliary system. 11th ed. Oxford: Wiley-Blackwell, 2002
2. Sethasine S, Jain D, Groszmann RJ, Garcia-Tsao G. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology 2012; 55: 1146-1153 [PMID: 22109744 DOI: 10.1002/hep.24805]
3. García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012; 57: 458-461 [PMID: 22504334 DOI: 10.1016/j.jhep.2012.03.007]
4. Bendtsen F, Krag A, Møller S. Treatment of acute variceal bleeding. Dig Liver Dis 2008; 40: 328-336 [PMID: 18243077 DOI: 10.1152/ajprenal.90407.2008]
5. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. J Hepatol 2010; 53: 558-567 [PMID: 20561700 DOI: 10.1016/j.jhep.2010.03.021]
6. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 2006; 43: S121-S131 [PMID: 16447289]
7. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Arterial compliance in patients with cirrhosis: Stroke volume-pulse pressure ratio as simplified index. Am J Physiol Gastrointest Liver Physiol 2001; 280: G584-G594 [PMID: 11254484]
8. Henriksen JH, Bendtsen F, Sørensen TI, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-1513 [PMID: 2583416]
9. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol 2012; 56 Suppl 1: S13-S24 [PMID: 22300462 DOI: 10.1016/S0168-8278(12)60003-8]
10. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med 2008; 29: 119-129 [PMID: 18036654]
11. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. 2nd ed. Malden: Blackwell, 2005: 139-155
12. Ginès P, Cárdenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008; 28: 43-58 [PMID: 18293276 DOI: 10.1055/s-2008-1040320]
13. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-278 [PMID: 18192456 DOI: 10.1136/gut.2006.112177]
14. Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 1988; 6: 350-358 [PMID: 3392385]
15. Lebrec D, Moreau R. Pathogenesis of portal hypertension. Eur J Gastroenterol Hepatol 2001; 13: 309-311 [PMID: 11338055]
16. Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. J Hepatol 2012; 57: 1135-1140 [PMID: 22749942 DOI: 10.1016/j.jhep.2012.06.024]
17. Bernardi M. Spontaneous bacterial peritonitis: From pathophysiology to prevention. Intern Emerg Med 2010; 5 Suppl 1: S37-S44 [PMID: 20865473 DOI: 10.1007/s11739-010-0446-x]
18. Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTPcyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38: 1508-1515 [PMID: 14647062]
19. Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-39 [PMID: 23121656 DOI: 10.1111/liv.12021]
20. Neugebauer H, Hartmann P, Krenn S, Glück T, Schölmerich J, Straub R, Wiest R. Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: Priming independent of liver cirrhosis. Liver Int 2008; 28: 1149-1157 [PMID: 18662280 DOI: 10.1111/j.1478-3231.2008.01829.x]
21. Yokomori H, Oda M, Yoshimura K, Watanabe S, Hibi T. Aberrant expressions of aquaporin-1 in association with capillarized sinusoidal endothelial cells in cirrhotic rat liver. Med Mol Morphol 2010; 43: 6-12 [PMID: 20340000 DOI: 10.1007/s00795-009-0475-6]
22. Steib CJ. Kupffer cell activation and portal hypertension. Gut 2011; 60: 1307-1308 [PMID: 21708827 DOI: 10.1136/gut.2011.242560]
23. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: Role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-581 [PMID: 11889082]
24. Marra F, Parola M. Cells in the Liver -Functions in Health and Disease. In: Gines P, Kamath PS, Arroyo V, editors. Chronic Liver Failure. Mechanisms and Management. 1 ed. New York: Springer, 2011: 3-32
25. Matsumura H, Shimizu Y, Ohsawa Y, Kawahara A, Uchiyama Y, Nagata S. Necrotic death pathway in Fas receptor signaling. J Cell Biol 2000; 151: 1247-1256 [PMID: 11121439]
26. Rockey DC. The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications. Clin Liver Dis 2000; 4: 319-355 [PMID: 11232195]
27. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
28. Henriksen JH. Degradation of Bioactive Substances: Physiology and Pathophysiology. Boca Raton: CRC Press, 1991
29. Gerbes AL, Witthaut R, Gülberg V, Thibault G, Bilzer M, Jüngst D. Role of the liver in splanchnic extraction of atrial natriuretic factor in the rat. Hepatology 1992; 16: 790-793 [PMID: 1387103]
30. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J Hepatol 2009; 51: 212-223 [PMID: 19447517 DOI: 10.1016/j.jhep.2009.03.008]
31. Nolan JP. The role of intestinal endotoxin in liver injury: A long and evolving history. Hepatology 2010; 52: 1829-1835 [PMID: 20890945 DOI: 10.1002/hep.23917]
32. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006; 26: 1175-1186 [PMID: 17105582]
33. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16: 1321-1329 [PMID: 20238398]
34. Friedman SL. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
35. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206 [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005]
36. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: Nearing the starting line. Sci Transl Med 2013; 5: 167sr1 [PMID: 23303606 DOI: 10.1126/scitranslmed. 3004700]
37. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10: 459-79, vii-viii [PMID: 17162223]
38. DeLeve LD. Liver sinusoidal endothelial cells and liver regeneration. J Clin Invest 2013; 123: 1861-1866 [PMID: 23635783 DOI: 10.1172/JCI66025]
39. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review. Comp Hepatol 2002; 1: 1 [PMID: 12437787]
40. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 2012; 32: 199-213 [PMID: 21745318 DOI: 10.1111/j.1478-3231.2011.02579.x]
41. Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, Szabo G, Zakhari S. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011; 300: G516-G525 [PMID: 21252049 DOI: 10.1152/ajpgi.00537.2010]
42. Mortensen C, Andersen O, Krag A, Bendtsen F, Møller S. High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2012; 24: 619-626 [PMID: 22441510 DOI: 10.1097/MEG.0b013e328351db6e]
43. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 95-107 [PMID: 15704042]
44. Henriksen JH, Møller S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In: Epstein M, editor. The kidney in liver disease. 4th ed. Philadelphia: Hanley and Belfus, 1996: 241-58
45. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32: 141-156 [PMID: 10728801]
46. Henriksen JH, Winkler K. Hepatic blood flow determination. A comparison of 99mTc-diethyl-IDA and indocyanine green as hepatic blood flow indicators in man. J Hepatol 1987; 4: 66-70 [PMID: 3571934]
47. Madsen JL, Søndergaard SB, Møller S. Meal-induced changes in splanchnic blood flow and oxygen uptake in middleaged healthy humans. Scand J Gastroenterol 2006; 41: 87-92 [PMID: 16373281]
48. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6: 287-298 [PMID: 3544222]
49. Hobolth L, Møller S, Grønbæk H, Roelsgaard K, Bendtsen F, Feldager Hansen E. Carvedilol or propranolol in portal hypertension? A randomized comparison. Scand J Gastroenterol 2012; 47: 467-474 [PMID: 22401315 DOI: 10.3109/00365521.20 12.666673]
50. Albillos A, Bañares R, González M, Catalina MV, Pastor O, Gonzalez R, Ripoll C, Bosch J. The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut 2007; 56: 259-264 [PMID: 16837532]
51. Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, García-Pagan JC, Bosch J. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 2013; 8: E58742 [PMID: 23520531 DOI: 10.1371/journal.pone.0058742]
52. Bendtsen F, Simonsen L, Henriksen JH. Effect on hemodynamics of a liquid meal alone and in combination with propranolol in cirrhosis. Gastroenterology 1992; 102: 1017-1023 [PMID: 1537493]
53. Morita H, Abe C. Negative feedforward control of body fluid homeostasis by hepatorenal reflex. Hypertens Res 2011; 34: 895-905 [PMID: 21716295 DOI: 10.1038/hr.2011.88]
54. Lautt WW. Regulatory processes interacting to maintain hepatic blood flow constancy: Vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res 2007; 37: 891-903 [PMID: 17854463]
55. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: Evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664-670 [PMID: 9203948]
56. Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003; 9: 32-39 [PMID: 12514771]
57. Jiménez-Sáenz M, Soria IC, Bernardez JR, Gutierrez JM. Renal sodium retention in portal hypertension and hepatorenal reflex: From practice to science. Hepatology 2003; 37: 1494; author reply 1494-1495 [PMID: 12774029]
58. Gülberg V, Haag K, Rössle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002; 35: 630-634 [PMID: 11870377]
59. Zipprich A, Steudel N, Behrmann C, Meiss F, Sziegoleit U, Fleig WE, Kleber G. Functional significance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology 2003; 37: 385-392 [PMID: 12540789]
60. Lautt WW, Greenway CV, Legare DJ. Effect of hepatic nerves, norepinephrine, angiotensin, and elevated central venous pressure on postsinusoidal resistance sites and intrahepatic pressures in cats. Microvasc Res 1987; 33: 50-61 [PMID: 3561267]
61. Møller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001; 61: 421-429 [PMID: 11681531]
62. Iwakiri Y. The molecules: Mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007; 41 Suppl 3: S288-S294 [PMID: 17975478]
63. Alam I, Bass NM, Bacchetti P, Gee L, Rockey DC. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol 2000; 95: 199-203 [PMID: 10638583]
64. Zipprich A, Mehal WZ, Ripoll C, Groszmann RJ. A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl-cirrhotic liver. Liver Int 2010; 30: 988-994 [PMID: 20500549 DOI: 10.1111/j.1478-3231.2010.02278.x]
65. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002; 35: 478-491 [PMID: 11826425]
66. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Donà S, Fagiuoli S, Sticca A, Zanus G, Cillo U, Frasson I, Destro C, Gatta A. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology 2007; 45: 223-229 [PMID: 17187409]
67. Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: Current challenges and future directions. Gut 2012; 61: 1219-1225 [PMID: 22661495 DOI: 10.1136/gutjnl-2012-302339]
68. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, Jalan R. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831-840 [PMID: 17680644]
69. Grønbaek H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther 2012; 36: 173-180 [PMID: 22591184 DOI: 10.1111/j.1365-2036.2012.05134.x]
70. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56 Suppl 1: S1-12 [PMID: 22300459 DOI: 10.1016/S0168-8278(12)60002-6]
71. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: Recent guidelines and beyond. Gut 2012; 61: 297-310 [PMID: 22147550 DOI: 10.1136/gutjnl-2011-300779]
72. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-2033 [PMID: 19885876 DOI: 10.1002/hep.23264]
73. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42 [PMID: 18293275 DOI: 10.1055/s-2008-1040319]
74. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-217 [PMID: 12500206]
75. Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52: 2044-2052 [PMID: 20979050 DOI: 10.1002/hep.23918]
76. Mortensen C, Karlsen S, Grønbæk H, Nielsen DT, Frevert S, Clemmesen JO, Møller S, Jensen JS, Bendtsen F. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. Liver Int 2013; 33: 1309-1315 [PMID: 23763259 DOI: 10.1111/liv.12205]
77. Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, Albillos A, Jiménez W, Arroyo V. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-1218 [PMID: 14578859]
78. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]
79. Leithead JA, Ferguson JW, Bates CM, Davidson JS, Lee A, Bathgate AJ, Hayes PC, Simpson KJ. The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut 2009; 58: 443-449 [PMID: 19001057 DOI: 10.1136/gut.2008.154120]
80. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-1501 [PMID: 7982650]
81. Fagundes C, Ginès P. Hepatorenal syndrome: A severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis 2012; 59: 874-885 [PMID: 22480795 DOI: 10.1053/j.ajkd.2011.12.032]
82. Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31: 858-863 [PMID: 10733540]
83. Tazi KA, Moreau R, Hervé P, Dauvergne A, Cazals-Hatem D, Bert F, Poirel O, Rabiller A, Lebrec D. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: Role of Akt signaling. Gastroenterology 2005; 129: 303-314 [PMID: 16012955]
84. Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis. Liver Int 2009; 29: 1189-1193 [PMID: 19508620 DOI: 10.1111/j.1478-3231.2009.02038.x]
85. Llach J, Ginès P, Arroyo V, Rimola A, Titó L, Badalamenti S, Jiménez W, Gaya J, Rivera F, Rodés J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-487 [PMID: 3335320]
86. Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986; 27: 1204-1209 [PMID: 3781335]
87. Møller S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan Med Bull 1998; 45: 1-14 [PMID: 9504263]
88. Møller S, Hillingsø J, Christensen E, Henriksen JH. Arterial hypoxaemia in cirrhosis: Fact or fiction? Gut 1998; 42: 868-874 [PMID: 9691928]
89. Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011; 60: 1254-1259 [PMID: 21504996 DOI: 10.1136/gut.2010.235473]
90. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: Pathophysiological basis of therapy and current management. J Hepatol 2003; 38 Suppl 1: S69-S89 [PMID: 12591187]
91. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157 [PMID: 2971015]
92. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997; 17: 505-519 [PMID: 9353862]
93. Schrier RW, Ecder T. Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation: Implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001; 68: 350-361 [PMID: 11687862]
94. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-541 [PMID: 9709047]
95. Møller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996; 31: 928-933 [PMID: 8888443]
96. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997; 26: 1111-1119 [PMID: 9186842]
97. Guevara M, Ginès P, Jiménez W, Sort P, Fernández-Esparrach G, Escorsell A, Bataller R, Bosch J, Arroyo V, Rivera F, Rodés J. Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-343 [PMID: 9453495]
98. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N, Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832 [PMID: 11433348]
99. Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2008; 295: G649-G653 [PMID: 18703639 DOI: 10.1152/ajpgi.90352.2008]
100. Ros J, Clària J, To-Figueras J, Planagumà A, Cejudo-Martín P, Fernández-Varo G, Martín-Ruiz R, Arroyo V, Rivera F, Rodés J, Jiménez W. Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93 [PMID: 11781284]
101. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98-103 [PMID: 15893841]
102. Huang HC, Haq O, Utsumi T, Sethasine S, Abraldes JG, Groszmann RJ, Iwakiri Y. Intestinal and plasma VEGF levels in cirrhosis: The role of portal pressure. J Cell Mol Med 2012; 16: 1125-1133 [PMID: 21801303 DOI: 10.1111/j.1582-4934.2011.01399.x]
103. Iwakiri Y, Grisham M, Shah V. Vascular biology and pathobiology of the liver: Report of a single-topic symposium. Hepatology 2008; 47: 1754-1763 [PMID: 18393322 DOI: 10.1002/hep.22203]
104. Bernardi M, Fornalè L, Di Marco C, Trevisani F, Baraldini M, Gasbarrini A, De Collibus C, Zacà F, Ligabue A, Colantoni A. Hyperdynamic circulation of advanced cirrhosis: A re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995; 22: 309-318 [PMID: 7608482]
105. Laffi G, Barletta G, La Villa G, Del Bene R, Riccardi D, Ticali P, Melani L, Fantini F, Gentilini P. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-898 [PMID: 9287981]
106. Gentilini P, Romanelli RG, Laffi G, Barletta G, Del Bene R, Messeri G, La Villa G. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: Effects of posture. J Hepatol 1999; 30: 632-638 [PMID: 10207804]
107. Møller S, Nørgaard A, Henriksen JH, Frandsen E, Bendtsen F. Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology 2004; 40: 811-819 [PMID: 15382169]
108. Henriksen JH, Bendtsen F, Gerbes AL, Christensen NJ, Ring-Larsen H, Sørensen TI. Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, betaadrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16: 1163-1170 [PMID: 1358779]
109. Brinch K, Møller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003; 39: 24-31 [PMID: 12821040]
110. Schrier RW. Water and sodium retention in edematous disorders: Role of vasopressin and aldosterone. Am J Med 2006; 119: S47-S53 [PMID: 16843085]
111. Møller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumes in cirrhosis: Relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003; 284: G970-G979 [PMID: 12606306]
112. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-1925 [PMID: 7498657]
113. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: Aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35: 605-612 [PMID: 11690706]
114. Møller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994; 21: 940-946 [PMID: 7699257]
115. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, Jiménez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447 [PMID: 15977202]
116. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 105-110 [PMID: 19837678 DOI: 10.1136/gut.2009.180570]
117. Bendtsen F, Henriksen JH, Sørensen TI. Long-term effects of oral propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis and oesophageal varices. Scand J Gastroenterol 1991; 26: 933-939 [PMID: 1947785]
118. Krag A, Møller S, Burroughs AK, Bendtsen F. Betablockers induce cardiac chronotropic incompetence. J Hepatol 2012; 56: 298-299 [PMID: 22173037 DOI: 10.1016/j.jhep.2011.04.033]
119. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025-1033 [PMID: 13096569]
120. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28: 59-69 [PMID: 18293277]
121. Zaky A, Lang JD, Treggiari M. Towards a better characterization of cirrhosis-associated cardiomyopathy? J Hepatol 2013; 59: 192-193 [PMID: 23415930 DOI: 10.1016/j.jhep.2013.02.001]
122. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44: 994-1002 [PMID: 16510203]
123. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-190 [PMID: 20462649 DOI: 10.1016/j.jhep.2010.02.023]
124. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34 [PMID: 9425913]
125. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009; 104: 2458-2466 [PMID: 19532126 DOI: 10.1038/ajg.2009.321]
126. Saner FH, Neumann T, Canbay A, Treckmann JW, Hartmann M, Goerlinger K, Bertram S, Beckebaum S, Cicinnati V, Paul A. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011; 24: 425-432 [PMID: 21276088 DOI: 10.1111/j.1432-2277.2011.01219. x]
127. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: Pathogenic mechanisms. World J Gastroenterol 2006; 12: 837-842 [PMID: 16521209]
128. Mani AR, Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. Hepatology 2006; 43: 847-856 [PMID: 16557556]
129. Møller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013; 167: 1101-1108 [PMID: 23041091 DOI: 10.1016/j.ijcard.2012.09.089]
130. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275 [PMID: 11454805]
131. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001; 36: 785-794 [PMID: 11495071]
132. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-748 [PMID: 10205217]
133. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, De CS, Riggio O. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002; 97: 142-148 [PMID: 11808939]
134. Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847 [PMID: 12454841]
135. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G, Giannattasio C, Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-1137 [PMID: 9362352]
136. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J, Genescà J. Cardiac alterations in cirrhosis: Reversibility after liver transplantation. J Hepatol 2005; 42: 68-74 [PMID: 15629509]
137. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15 [PMID: 11751653]
138. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995; 22: 326-332 [PMID: 7608484]
139. Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, Kaplan MM. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998; 43: 1701-1707 [PMID: 9724156]
140. Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, Vilstrup H. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011; 31: 534-540 [PMID: 21382164]
141. Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, Bettencourt P, Fraga J, Gama V. Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. Eur J Intern Med 2014; 25: 241-246 [PMID: 24485543 DOI: 10.1016/j.ejim.2014.01.011]
142. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6: S44-S52 [PMID: 10915191]
143. Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, Calchera I, Mancia G. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol 2005; 51: 179-186 [PMID: 15990707]
144. Gaskari SA, Honar H, Lee SS. Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 329-337 [PMID: 16741552]
145. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-284 [PMID: 8833359]
146. Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40: 239-246 [PMID: 14739094]
147. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: Relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-1517 [PMID: 12970147]
148. Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, Pieruzzi F, Vincenti A, Stella A, Mancia G, Stramba-Badiale M. QT interval prolongation and decreased heart rate variability in cirrhotic patients: Relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond) 2009; 116: 851-859 [PMID: 19076059 DOI: 10.1042/CS20080325]
149. Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: Innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol 2012; 6: 57-66 [PMID: 22149582 DOI: 10.1586/egh.11.86]
150. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23: 1128-1134 [PMID: 8621144]
151. Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, Lenzi B, Caraceni P, Domenicali M, Cavazza M, Bernardi M. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 2012; 32: 1510-1515 [PMID: 22776742 DOI: 10.1111/j.1478-3231.2012.02847.x]
152. Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013; 34: 2804-2811 [PMID: 23853073 DOI: 10.1093/eurheartj/eht246]
153. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32: 859-865 [PMID: 11003635]
154. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880 [PMID: 15516683]
155. Grace JA, Angus PW. Hepatopulmonary syndrome: Update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol 2013; 28: 213-219 [PMID: 23190201]
156. Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology 2014; 59: 1627-1637 [PMID: 24089295 DOI: 10.1002/hep.26745]
157. Scarlata S, Conte ME, Cesari M, Gentilucci UV, Miglioresi L, Pedone C, Picardi A, Ricci GL, Incalzi RA. Gas exchanges and pulmonary vascular abnormalities at different stages of chronic liver disease. Liver Int 2011; 31: 525-533 [PMID: 21382163 DOI: 10.1111/j.1478-3231.2011.02467.x]
158. Gaines DI, Fallon MB. Hepatopulmonary syndrome. Liver Int 2004; 24: 397-401 [PMID: 15482333]
159. Deibert P, Allgaier HP, Loesch S, Müller C, Olschewski M, Hamm H, Maier KP, Blum HE. Hepatopulmonary syndrome in patients with chronic liver disease: Role of pulse oximetry. BMC Gastroenterol 2006; 6: 15 [PMID: 16638132]
160. Møller S, Krag A, Madsen JL, Henriksen JH, Bendtsen F. Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. Liver Int 2009; 29: 1528-1537 [PMID: 19725890 DOI: 10.1111/j.1478-3231.2009.02103.x]
161. Luo B, Tang L, Wang Z, Zhang J, Ling Y, Feng W, Sun JZ, Stockard CR, Frost AR, Chen YF, Grizzle WE, Fallon MB. Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 2005; 129: 682-695 [PMID: 16083721]
162. Machicao VI, Fallon MB. Hepatopulmonary syndrome. Semin Respir Crit Care Med 2012; 33: 11-16 [PMID: 22447256 DOI: 10.1055/s-0032-1301730]
163. Zhang J, Fallon MB. Hepatopulmonary syndrome: Update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol 2012; 9: 539-549 [PMID: 22751459 DOI: 10.1038/nrgastro.2012.123]
164. Grace JA, Burrell LM, Patel SK. Angiotensin-converting enzyme 2 polymorphisms and cardiovascular risk. Intern Med J 2012; 42: 1167 [PMID: 23046195 DOI: 10.1111/j.1445-5994.2012.02909.x]
165. Krishnamurthy GT, Krishnamurthy S. Nuclear Hepatology. a Textbook of Hepatobiliary Diseases. Berlin: Springer, 2000
166. Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, Kowdley KV. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: Role of increased pulmonary artery pressure. J Clin Gastroenterol 2004; 38: 590-594 [PMID: 15232363]
167. Boyer TD, Haskal ZJ. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: Update 2009. Hepatology 2010; 51: 306 [PMID: 19902484 DOI: 10.1002/hep.23383]
168. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505]
169. Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, Wiesner RH, Krowka MJ. Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era. Hepatology 2013; 57: 2427-2435 [PMID: 22996424 DOI: 10.1002/hep.26070]
170. Katsuta Y, Zhang XJ, Kato Y, Shimizu S, Komeichi K, Ohsuga M, Higashi H, Satomura K, Takano T. Hemodynamic features and impaired arterial oxygenation in patients with portopulmonary hypertension. Hepatol Res 2005; 32: 79-88 [PMID: 15978871]
171. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111 [PMID: 16123953]
172. Battistini B, Dussault P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Pulm Pharmacol Ther 1998; 11: 79-88 [PMID: 9918740]
173. Lüscher TF. Endothelin: Systemic arterial and pulmonary effects of a new peptide with potent biologic properties. Am Rev Respir Dis 1992; 146: S56-S60 [PMID: 1332560]
174. Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, Fallon MB. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: A potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003; 38: 556-563 [PMID: 12713865]
175. Giusca S, Jinga M, Jurcut C, Jurcut R, Serban M, Ginghina C. Portopulmonary hypertension: From diagnosis to treatment. Eur J Intern Med 2011; 22: 441-447 [PMID: 21925050 DOI: 10.1016/j.ejim.2011.02.018]
176. Krowka MJ, Cartin-Ceba R. Portopulmonary hypertension: Formidable dual threat versus hopeful dual therapy. Liver Transpl 2014; 20: 635-636 [PMID: 24711442 DOI: 10.1002/lt.23885]
177. Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005; 11: 1026-1027 [PMID: 16123957]
178. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112: 980-986 [PMID: 9377962]
179. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med 2008; 75: 121-12, 125-30, 133 passim [PMID: 18290356]
180. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102 [PMID: 17652314]
181. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36 Suppl 3: 67-70 [PMID: 16919014]
182. Hollatz TJ, Musat A, Westphal S, Decker C, D'Alessandro AM, Keevil J, Zhanhai L, Runo JR. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl 2012; 18: 686-695 [PMID: 22315210 DOI: 10.1002/lt.23407]
183. Rodríquez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). J Hepatol 2005; 42: 924-927 [PMID: 15973780]
184. Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: Implications for liver transplantation. Clin Chest Med 2005; 26: 587-97, vi [PMID: 16263398]
185. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077 [PMID: 19003880 DOI: 10.1002/hep.22605]
186. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31 [PMID: 17331245]
187. Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, Burroughs AK. Renal failure and cirrhosis: A systematic review of mortality and prognosis. J Hepatol 2012; 56: 810-818 [PMID: 22173162 DOI: 10.1016/j.jhep.2011.10.016]
188. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290 [PMID: 19776409 DOI: 10.1056/NEJMra0809139]
189. Stremitzer S, Tamandl D, Kaczirek K, Maresch J, Abbasov B, Payer BA, Ferlitsch A, Gruenberger T. Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 1752-1758 [PMID: 22009385 DOI: 10.1002/bjs.7672]
190. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008; 84: 662-670 [PMID: 19201943 DOI: 10.1136/gut.2006.107789]
191. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709 [PMID: 21325171 DOI: 10.1136/gut.2010.236133]
192. Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, Sarin SK, Bernardi M. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: Report from the International Club of Ascites. Liver Int 2013; 33: 16-23 [PMID: 22507181 DOI: 10.1111/j.1478-3231.2012.02807.x]
193. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, Jalan R. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008; 134: 111-119 [PMID: 18166350 DOI: 10.1053/j.gastro.2007]
194. Møller S, Krag A. Cardiorenal syndrome -A new entity? In: Gerbes A, editor. Hyponatremia and hepatorenal syndrome: Progress in treatment. Basel: Karger, 2011: 102-111
195. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: Relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007; 292: H2966-H2972 [PMID: 17293491]
196. Schmidt LE, Ring-Larsen H. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis. Curr Pharm Des 2006; 12: 4637-4647 [PMID: 17168767]
197. Henriksen JH, Fuglsang S, Bendtsen F. Fourier analysis of arterial pulse in patients with advanced cirrhosis indicates reduced wave reflections that may protect against manifest cardiac dysfunction. Gut 2012; 61: 1239-1240 [PMID: 22138534 DOI: 10.1136/gutjnl-2011-301598]
198. Schrier RW. Decreased effective blood volume in edematous disorders: What does this mean? J Am Soc Nephrol 2007; 18: 2028-2031 [PMID: 17568020]
199. Krag A, Bendtsen F, Burroughs AK, Møller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses 2012; 79: 53-55 [PMID: 22537409 DOI: 10.1016/j.mehy.2012.03.032]
200. Theocharidou E, Krag A, Bendtsen F, Møller S, Burroughs AK. Cardiac dysfunction in cirrhosis -does adrenal function play a role? A hypothesis. Liver Int 2012; 32: 1327-1332 [PMID: 22292920 DOI: 10.1111/j.1478-3231.2011.02751.x]
201. Galbois A, Rudler M, Massard J, Fulla Y, Bennani A, Bonnefont-Rousselot D, Thibault V, Reignier S, Bourrier A, Poynard T, Thabut D. Assessment of adrenal function in cirrhotic patients: Salivary cortisol should be preferred. J Hepatol 2010; 52: 839-845 [PMID: 20385427 DOI: 10.1016/j.jhep.2010.01.026]
202. Trifan A, Chiriac S, Stanciu C. Update on adrenal insufficiency in patients with liver cirrhosis. World J Gastroenterol 2013; 19: 445-456 [PMID: 23382623 DOI: 10.3748/wjg.v19. i4.445]
203. Acevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, Roca D, Jimenez W, Ginès P, Arroyo V. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology 2013; 58: 1757-1765 [PMID: 23728792 DOI: 10.1002/hep.26535]
204. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS. Acute-on chronic liver failure. J Hepatol 2012; 57: 1336-1348 [PMID: 22750750 DOI: 10.1016/j.jhep.2012.06.026]